Genetic Study of Young Patients With Colorectal Cancer
A Prospective Study Of The Prognostic Significance Of Microsatellite Instability In Patients With Early Age-Of-Onset Colorectal Cancer
2 other identifiers
observational
651
2 countries
73
Brief Summary
RATIONALE: Identifying gene mutations (microsatellite instability) may allow doctors to plan effective treatment for patients who develop colorectal cancer at an early age. PURPOSE: Genetic trial to determine the significance of gene mutations in helping predict the outcome of treatment in patients who develop stage I, stage II, or stage III colorectal cancer at an early age.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2002
Typical duration for all trials
73 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2002
CompletedFirst Submitted
Initial submission to the registry
September 6, 2002
CompletedFirst Posted
Study publicly available on registry
January 27, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2004
CompletedJuly 6, 2016
July 1, 2016
2.6 years
September 6, 2002
July 1, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
overall survival
Up to 2 years
Study Arms (1)
Group 1
Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline. The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance. Patients may be referred for genetic counseling.
Interventions
Eligibility Criteria
Patients diagnosed with adenocarcinoma of the colon or rectum.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (73)
Providence Cancer Center
Mobile, Alabama, 36608, United States
Mobile Infirmary Medical Center
Mobile, Alabama, 36640-0460, United States
Arrowhead Regional Medical Center
Colton, California, 92324-1819, United States
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000, United States
UCSF Comprehensive Cancer Center
San Francisco, California, 94115, United States
Morton Plant Hospital
Clearwater, Florida, 33756, United States
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308, United States
Shands Cancer Center at the University of Florida Health Science Center
Gainesville, Florida, 32610-100277, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497, United States
Surgical Oncology of Northeast Georgia
Gainesville, Georgia, 30501, United States
Northwest Community Hospital
Arlington Heights, Illinois, 60005, United States
Rush Copley Medical Center
Aurora, Illinois, 60504-4206, United States
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013, United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470, United States
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153, United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202, United States
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309, United States
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1009, United States
Central Baptist Hospital
Lexington, Kentucky, 40503-9985, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932, United States
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
St. Agnes Cancer Center
Baltimore, Maryland, 21229, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805, United States
UMASS Memorial Cancer Center - University Campus
Worcester, Massachusetts, 01655, United States
Great Lakes Cancer Institute - McLaren
Flint, Michigan, 48532, United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455, United States
Digestive Health Specialists, P.A.
Tupelo, Mississippi, 38801, United States
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203, United States
Siteman Cancer Center at Barnes-Jewish Hospital
St Louis, Missouri, 63110, United States
Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha
Omaha, Nebraska, 68114-4199, United States
Cancer Center at Creighton University Medical Center
Omaha, Nebraska, 68131-2197, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642, United States
Presbyterian Hospital
Charlotte, North Carolina, 28204, United States
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861, United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710, United States
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1082, United States
Akron General's McDowell Cancer Center
Akron, Ohio, 44302, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
Integris Oncology Services
Oklahoma City, Oklahoma, 73112, United States
Natalie Warren Bryant Cancer Center
Tulsa, Oklahoma, 74136, United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4283, United States
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212-4772, United States
UPMC Cancer Center at Magee-Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224, United States
Sarah Cannon Cancer Center at Parkridge Medical Center
Chattanooga, Tennessee, 37404-3285, United States
Baptist Cancer Institute at Baptist Memorial Hospital - Memphis
Memphis, Tennessee, 38120, United States
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
Nashville, Tennessee, 37232-6860, United States
Baptist Hospital
Nashville, Tennessee, 37236, United States
Presbyterian Hospital of Dallas
Dallas, Texas, 75231, United States
Baylor University Medical Center
Dallas, Texas, 75246, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
Methodist Hospital
Houston, Texas, 77030, United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84132, United States
Fletcher Allen Health Care - Medical Center Campus
Burlington, Vermont, 05401, United States
INOVA Fair Oaks Hospital
Fairfax, Virginia, 22033, United States
Inova Fairfax Hospital
Falls Church, Virginia, 22042-3300, United States
Massey Cancer Center at Virginia Commonwealth University
Richmond, Virginia, 23298-0037, United States
Associated Surgeons P.S.
Spokane, Washington, 99204, United States
Sacred Heart Medical Center
Spokane, Washington, 99204, United States
Providence Cancer Center at Holy Family Hospital
Spokane, Washington, 99208, United States
Deaconess Medical Center
Spokane, Washington, 99210-0248, United States
Fox Valley Surgical Associates at Appleton Medical Center
Appleton, Wisconsin, 54911-3454, United States
Appleton Medical Center
Appleton, Wisconsin, 54911, United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-7375, United States
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, 53226, United States
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226, United States
Regional Cancer Care at Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, P7B 6V4, Canada
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jose G. Guillem, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2002
First Posted
January 27, 2003
Study Start
May 1, 2002
Primary Completion
December 1, 2004
Study Completion
December 1, 2004
Last Updated
July 6, 2016
Record last verified: 2016-07